NIPT Poses Minimal Risk to the Mother or Baby!
Evolving noninvasive screening options, such as noninvasive prenatal tests (NIPT), offer early genetic screening for chromosomal conditions using just one tube of blood—as early as 10 weeks into a patient’s pregnancy.
We offer NIPT testing by next-generation sequencing using Illumina NGS technology as a service to analyze cell free fetal and maternal DNA from a blood sample to screen for common chromosome conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome).
Additional screening is available for sex chromosome aneuploidies and select microdeletions in singleton pregnancies. In twin pregnancies, screening for aneuploidy in chromosomes 21, 18, and 13 and the option to screen for the absence of the Y chromosome is available.
NGS is the most-published method for performing NIPT
99.7% of NIPT samples in published studies were run on Illumina NGS technology
